Microbot Medical Overview
Microbot Medical specializes in transformational robotic technologies, focused primarily on the endovascular space. Its LIBERTY Robotic System is the world’s first single-use endovascular robotic system focused on increasing access to robotic technology and revolutionizing the way endovascular procedures are performed. LIBERTY is the first ever single-use endovascular surgical robotic system designed to streamline endovascular procedures. In August 2016, U.S.-based StemCells merged with Microbot Medical. In May 2018, the company announced its acquisition of a novel, patent-protected technology from CardioSert. Microbot Medical is now the owner of this technology, including all research and development information, technical know-how, and intellectual property.
Cumulative Funding Raised Over Time ($)
$10.0MDec 2019
$23.0MFeb 2025
$26.0MJan 2019
$31.9MJan 2019
$34.4MJan 2019
$41.4MJan 2025
$44.4MJul 2012
$54.4MJun 2017
$56.4MJun 2023
$57.9MJun 2023
$60.3MJun 2024
Latest News
growth-positive
Down 28.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Microbot Medical (MBOT)
Microbot Medical Inc. (MBOT) has experienced significant selling pressure, with its stock price dropping by 28.2% over the past four weeks. However, the stock is now considered oversold, with a Relative Strength Index (RSI) of 26.65, suggesting a potential rebound. Analysts have raised their earnings estimates for the company, with a 20% increase in the consensus EPS estimate over the last 30 days. This upward trend in earnings estimates, combined with a Zacks Rank #2 (Buy), indicates a positive outlook for the stock. Investors may see this as an opportunity for entry, anticipating a price appreciation in the near term.
growth-positive
Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting
Microbot Medical Inc. is set to commercially exhibit its LIBERTY® Endovascular Robotic System at the Symposium on Clinical Interventional Oncology in Miami, marking its first U.S. medical meeting presence post-FDA clearance. The company has completed the recruitment of its commercial leadership team to support the launch of the LIBERTY® System, planned for Q4. Justin Bourne and Dani Kulp have joined as Regional Sales Director and Sales Training Director, respectively, to drive sales strategy and training. The LIBERTY® System, which received FDA 510(k) clearance in September, will be showcased with live demos to engage potential users.
Product StageManagement Changes
growth-positive
Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
Microbot Medical Inc. is set to launch its FDA-cleared LIBERTY® Endovascular Robotic System in Q4 2025, with a broader release planned for April 2026. The company has partnered with a U.S.-based third-party logistics provider to support the commercialization process. This partnership will help ensure efficient inventory management and customer support, leveraging the logistics providers expertise in the medical device industry. The LIBERTY® System is a single-use, remotely operated robotic solution designed for precision and safety in endovascular procedures. The company is focused on transforming endovascular care through advanced robotic technology.
Product StagePartners
growth-positive
Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
Microbot Medical Inc. announced the third and final closing of its exercise of certain outstanding preferred investment options, resulting in the purchase of 13,989,115 shares of common stock. The company raised $25.2 million in the first closing, $1.2 million in the second, and $2.8 million in the third, with potential additional gross proceeds of approximately $63 million upon full exercise of short-term preferred investment options. The new short-term series J preferred investment options have an exercise price of $4.50 per share and will be exercisable six months after issuance, with a term of two years. This investment is expected to positively impact the companys growth.
Investment
growth-positive
Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio
Microbot Medical Inc., a developer of the LIBERTY® Endovascular Robotic System, has received its first patent in Japan, adding to its existing patents in the U.S., China, and Israel. The company recently obtained FDA clearance for the LIBERTY® System and is focusing on the U.S. market while exploring global expansion in markets that accept FDA-cleared devices. The LIBERTY® System is a single-use, remotely operated robotic solution designed for precision and safety in endovascular procedures. The company aims to capitalize on its strong intellectual property portfolio to drive future growth.
Product StageFDA approvedExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $60.69M |
| Last funding | $13M |
| Stage | Public |
| Rounds | 13 |
| Investors | 2 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | microbotmedical.com |
| Careers | Careers page |
Locations
HaYozma St 6, Yokne'am Illit, Israel
288 Grove St suite 388, Braintree, MA 02184, USA
Photos & Videos
2 item(s)
Microbot Medical Business
Business models
B2B
Product stage
R&D
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Machinery & RoboticsTags (19)
gastroenterologyvascularroboticsminimally-invasiveneurologyendoscopycolonoscopyurologydrug-deliveryimagingmedical-deviceshospitalsdoctorsoptronicsneurovascularmedical-equipmenttelemedicinemedical-technologiescardiovascularGeographic Markets
IndiaEuropeMicrobot Medical Financials
$60.69M
Total funding
Undisclosed
Capital raised
$13M
Last funding
Public
Funding stage
13
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$10.0MDec 2019
$23.0MFeb 2025
$26.0MJan 2019
$31.9MJan 2019
$34.4MJan 2019
$41.4MJan 2025
$44.4MJul 2012
$54.4MJun 2017
$56.4MJun 2023
$57.9MJun 2023
$60.3MJun 2024
Private Equity Funding
PIPE
Feb 2025
$13M
PIPE
Jan 2025
$7M
PIPE
Jun 2024
$2.35M
Undisclosed Investor(s)
PIPE
Jun 2023
$2M
Undisclosed Investor(s)
PIPE
Jun 2023
$1.5M
Undisclosed Investor(s)
PIPE
Dec 2019
$10M
Undisclosed Investor(s)
PIPE
Jan 2019
$3M
Undisclosed Investor(s)
PIPE
Jan 2019
$5.9M
Undisclosed Investor(s)
PIPE
Jan 2019
$2.5M
Undisclosed Investor(s)
PIPE
Jun 2017
$10M
Undisclosed Investor(s)
A Round
Jul 2012
$3M
MEDX Ventures Group, Undisclosed Investor(s)
Non-Equity Funding
GrantEvent
Jun 2023
$440K
Israel Innovation Authority (Lead)
Public Offering / Exit
POEvent
Nov 2016
Undisclosed
Mergers & Acquisitions
MNAEvent
Oct 2022
Undisclosed
MNAEvent
May 2018
$370K
Microbot Medical Lifecycle
Cumulative Funding Raised Over Time
$10.0MDec 2019
$23.0MFeb 2025
$26.0MJan 2019
$31.9MJan 2019
$34.4MJan 2019
$41.4MJan 2025
$44.4MJul 2012
$54.4MJun 2017
$56.4MJun 2023
$57.9MJun 2023
$60.3MJun 2024
All Events
PIPE
Feb 2025
$13M
PIPE
Jan 2025
$7M
PIPE
Jun 2024
$2.35M
Undisclosed Investor(s)
PIPE
Jun 2023
$2M
Undisclosed Investor(s)
PIPE
Jun 2023
$1.5M
Undisclosed Investor(s)
PIPE
Dec 2019
$10M
Undisclosed Investor(s)
PIPE
Jan 2019
$3M
Undisclosed Investor(s)
PIPE
Jan 2019
$5.9M
Undisclosed Investor(s)
PIPE
Jan 2019
$2.5M
Undisclosed Investor(s)
PIPE
Jun 2017
$10M
Undisclosed Investor(s)
A Round
Jul 2012
$3M
MEDX Ventures Group, Undisclosed Investor(s)
GrantEvent
Jun 2023
$440K
Israel Innovation Authority (Lead)
POEvent
Nov 2016
Undisclosed
MNAEvent
Oct 2022
Undisclosed
MNAEvent
May 2018
$370K
Microbot Medical News
163 articles
growth-positive
Down 28.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Microbot Medical (MBOT)
Microbot Medical Inc. (MBOT) has experienced significant selling pressure, with its stock price dropping by 28.2% over the past four weeks. However, the stock is now considered oversold, with a Relative Strength Index (RSI) of 26.65, suggesting a potential rebound. Analysts have raised their earnings estimates for the company, with a 20% increase in the consensus EPS estimate over the last 30 days. This upward trend in earnings estimates, combined with a Zacks Rank #2 (Buy), indicates a positive outlook for the stock. Investors may see this as an opportunity for entry, anticipating a price appreciation in the near term.
growth-positive
Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting
Microbot Medical Inc. is set to commercially exhibit its LIBERTY® Endovascular Robotic System at the Symposium on Clinical Interventional Oncology in Miami, marking its first U.S. medical meeting presence post-FDA clearance. The company has completed the recruitment of its commercial leadership team to support the launch of the LIBERTY® System, planned for Q4. Justin Bourne and Dani Kulp have joined as Regional Sales Director and Sales Training Director, respectively, to drive sales strategy and training. The LIBERTY® System, which received FDA 510(k) clearance in September, will be showcased with live demos to engage potential users.
Product StageManagement Changes
growth-positive
Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
Microbot Medical Inc. is set to launch its FDA-cleared LIBERTY® Endovascular Robotic System in Q4 2025, with a broader release planned for April 2026. The company has partnered with a U.S.-based third-party logistics provider to support the commercialization process. This partnership will help ensure efficient inventory management and customer support, leveraging the logistics providers expertise in the medical device industry. The LIBERTY® System is a single-use, remotely operated robotic solution designed for precision and safety in endovascular procedures. The company is focused on transforming endovascular care through advanced robotic technology.
Product StagePartners
growth-positive
Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
Microbot Medical Inc. announced the third and final closing of its exercise of certain outstanding preferred investment options, resulting in the purchase of 13,989,115 shares of common stock. The company raised $25.2 million in the first closing, $1.2 million in the second, and $2.8 million in the third, with potential additional gross proceeds of approximately $63 million upon full exercise of short-term preferred investment options. The new short-term series J preferred investment options have an exercise price of $4.50 per share and will be exercisable six months after issuance, with a term of two years. This investment is expected to positively impact the companys growth.
Investment
growth-positive
Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio
Microbot Medical Inc., a developer of the LIBERTY® Endovascular Robotic System, has received its first patent in Japan, adding to its existing patents in the U.S., China, and Israel. The company recently obtained FDA clearance for the LIBERTY® System and is focusing on the U.S. market while exploring global expansion in markets that accept FDA-cleared devices. The LIBERTY® System is a single-use, remotely operated robotic solution designed for precision and safety in endovascular procedures. The company aims to capitalize on its strong intellectual property portfolio to drive future growth.
Product StageFDA approvedExpand
growth-positive
All You Need to Know About Microbot Medical (MBOT) Rating Upgrade to Buy
Microbot Medical Inc. (MBOT) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates. This upgrade reflects an upward trend in the companys earnings potential, which is expected to positively influence its stock price. The Zacks rating system, which tracks consensus EPS estimates, plays a crucial role in guiding investment decisions by highlighting changes in earnings potential. The upgrade suggests an improvement in Microbot Medicals underlying business, which could attract institutional investors and lead to increased stock value. The Zacks Rank system has a strong track record of predicting stock movements based on earnings estimate revisions.
growth-positive
Miocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System
Microbot Medical Inc., a company specializing in advanced robotic technology for endovascular procedures, has received FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System. This clearance marks a significant milestone as the company prepares for commercialization in the U.S. The LIBERTY® system is noted for being the first single-use, remotely operated robotic solution designed to enhance precision, efficiency, and safety in endovascular care. The companys CEO, Harel Gadot, will discuss these developments in an interview on Benzinga All Access. The announcement is expected to positively impact the companys growth as it enters the U.S. market.
Product StageFDA approved/pending approval
growth-negative
Microbot (MBOT) Extends 4-Day Decline on $63-Million Fundraising Program
Microbot Medical Inc. (NASDAQ:MBOT) experienced a significant decline in its stock price, falling 6.93% to $3.09, as investors reacted negatively to a fundraising program that could potentially dilute existing shares. The company raised $25.2 million from an options exercise and plans a second offering to raise an additional $4 million. The funds are intended for the development and commercialization of its LIBERTY Robotic System, potential acquisitions, and other corporate purposes. Despite the potential of Microbot, the article suggests that AI stocks may offer better returns. The second offering is set to close on October 15.
Investment
growth-positive
Why Microbot Medical (MBOT) Is Up After FDA Clears LIBERTY System and $92M Funding Announced
Microbot Medical has received FDA 510(k) clearance for its LIBERTY® System, marking it as the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. This approval allows the company to commercialize the system in the U.S. and has led to agreements to raise up to $92.2 million through preferred investment options. The company is transitioning from clinical development to commercialization, focusing on ramping up sales and securing hospital partnerships. Despite the positive developments, Microbot Medical remains unprofitable, with risks of shareholder dilution and commercial execution challenges.
Product StageInvestment
growth-positive
Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
Microbot Medical Inc. announced the first closing of its exercise of certain outstanding preferred investment options, raising approximately $25.2 million, with an additional $4 million expected from a second closing. The company has the potential to raise up to $63 million in aggregate gross proceeds upon full exercise of short-term preferred investment options. The proceeds will be used for the development and commercialization of the LIBERTY® Robotic System, potential acquisitions, and other corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The second closing is expected by October 15, 2025.
Investment
growth-positive
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds
Microbot Medical Inc. announced definitive agreements for the exercise of preferred investment options, potentially raising up to $92.2 million. The first closing is expected to yield $25.2 million, with a second closing anticipated to bring in $4 million. Additional proceeds of $63 million could be realized if new short-term series J preferred investment options are fully exercised. H.C. Wainwright & Co. is the exclusive placement agent. The funds will support the development and commercialization of Microbots LIBERTY® Robotic System, potential acquisitions, and expansion of applications from its IP portfolio.
Investment
growth-positive
Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System
Microbot Medical Inc. has received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, marking a significant regulatory milestone. This clearance allows the company to commercialize the LIBERTY system in the U.S. market, aiming to expand its presence in the robotic surgery field. The LIBERTY system is designed to enhance precision and safety in endovascular procedures while minimizing radiation exposure. Following the announcement, Microbots shares surged, reflecting investor confidence in the companys growth prospects. The systems unique design is expected to drive faster adoption, offering a competitive advantage over traditional robotic platforms. Microbot plans to continue gathering clinical data as part of its commercial launch strategy.
Product StageFDA approved/pending approval
growth-positive
Microbot receives 510(k) clearance for endovascular robot
Microbot Medical has received 510(k) clearance from the FDA for its Liberty Endovascular Robotic System, allowing the company to market the system for peripheral endovascular procedures. The system is designed to reduce radiation exposure and physical strain on physicians while simplifying setup and operation. Microbot plans to commercialize the system in the U.S. and pursue global market entry. The company secured a grant of approximately $630,000 to enhance its manufacturing capabilities. Siemens Healthineers, which previously acquired Corindus Vascular Robotics, exited the robotic-assisted endovascular cardiology business in 2023, leaving an opportunity for Microbot in the market.
Product StageInvestment
growth-positive
REMINDER: Microbot Medical to Highlight FDA 510(k) Clearance of the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference
Microbot Medical Inc. announced the FDA clearance of its LIBERTY® Endovascular Robotic System, marking a significant milestone for the company. The LIBERTY® System is the first single-use, remotely operated robotic system designed for peripheral endovascular procedures. This announcement was made during the H.C. Wainwright Annual Investor Conference, where CEO Harel Gadot highlighted the systems potential to transform endovascular care. The company is focused on innovation and holds a strong intellectual property portfolio. The FDA approval is expected to positively impact the companys growth as it transitions to a commercially focused entity. However, the company acknowledges potential risks, including market conditions and geopolitical uncertainties.
FDA approved/pending approval
growth-positive
Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has announced that its LIBERTY® Endovascular Robotic System has received FDA 510(k) clearance, marking it as the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. This clearance allows the company to move forward with commercialization plans in the U.S., targeting approximately 2.5 million annual procedures. The LIBERTY® system aims to transform endovascular robotics by offering advanced technology without the need for extensive capital equipment. The pivotal study showed 100% success in navigation and significant radiation reduction for physicians. The company plans to continue collecting clinical data during the commercial launch, which is set for Q4 2025.
Product StageFDA approved/pending approval
growth-positive
Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market
Microbot Medical Inc. has been granted a new U.S. patent for its LIBERTY Endovascular Robotic System, which enhances its flexibility and broadens its potential applications. This patent expands the companys addressable market from 2.5 million to over six million annual procedures in the U.S., significantly increasing its revenue potential. The patent strengthens Microbots intellectual property portfolio, positioning it for future growth and potential strategic partnerships. While the LIBERTY system is still under FDA review for 510(k) clearance, the patent provides a strategic advantage as the company prepares for commercialization. Following the announcement, Microbots shares rose by 7.1%, and the companys market capitalization is currently $140.7 million.
Product StageFDA approved/pending approval
growth-positive
Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications
Microbot Medical Inc. announced the granting of a new patent by the USPTO for its LIBERTY® Endovascular Robotic System, which enhances its intellectual property portfolio. This patent allows for modular and customizable features, potentially expanding the systems applicability to a broader range of endovascular procedures. The company views this development as a significant step towards increasing its Total Addressable Market. Currently, the LIBERTY® system is an investigational device pending FDA 510(k) clearance and is not yet available for sale in the U.S. Microbot Medical is focused on scaling its commercial readiness plans as it awaits FDA approval.
Product Stage
growth-positive
DIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of Directors
DIH Holding US, Inc., a global provider of advanced robotic devices for rehabilitation, announced the appointment of Scott R. Burell to its Board of Directors. Burell, a seasoned healthcare finance executive, brings extensive experience in leading public life sciences companies through complex transactions and growth phases. His appointment is expected to strengthen DIHs board as the company continues to execute its growth strategy in the rehabilitation robotics market. The board now comprises six members, including four independent members, reinforcing the companys commitment to strong governance. DIH aims to improve the lives of people with disabilities through advanced rehabilitation technologies.
Management Changes
growth-positive
Microbot Medical secures grant for endovascular robotic system
Microbot Medical has received a non-dilutive grant of approximately $630,000 from the Israel Innovation Authority to enhance its manufacturing capabilities and move towards the commercialization of its Liberty endovascular robotic system. The system, designed for endovascular procedures, is pending FDA approval. Recent milestones include the successful results of the ACCESS-PVI pivotal study, which demonstrated the feasibility and safety of the Liberty system, and securing a patent in China for robotic control technology. Microbot Medical has also partnered with Emory University to explore the autonomous capabilities of the Liberty system.
InvestmentProduct StagePartners
growth-positive
Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities
Microbot Medical Inc. has received a non-dilutive grant of approximately $630,000 from the Israel Innovation Authority to support the commercialization of its LIBERTY® Endovascular Robotic System. This funding will enhance the companys manufacturing capabilities as it awaits FDA marketing clearance. The grant is seen as a validation of Microbots technology and reflects confidence in its ability to scale manufacturing. The LIBERTY® System is an investigational device pending FDA 510(k) clearance and is not yet available for sale in the U.S. The company aims to redefine endovascular robotics with its single-use, fully disposable system.
InvestmentFDA approved/pending approvalPartners
growth-positive
Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales
Microbot Medical Inc. has appointed Christina Bailey as the new Vice President of Sales to strengthen its commercial leadership. Bailey, a former U.S. Olympian with extensive experience in medical device sales, is expected to lead the sales team for the anticipated launch of the LIBERTY Endovascular Robotic System. The LIBERTY system is currently an investigational device pending FDA 510(k) clearance and is not yet available for sale in the U.S. Microbot Medical aims to redefine endovascular robotics with its single-use, fully disposable robotic system. The company is focused on transitioning to a commercially focused entity and is preparing for the potential market introduction of its innovative product.
Management Changes
growth-positive
Microbot Medical Secures China Patent for LIBERTY System, Eyes Q3 2025 US Launch
Microbot Medical Inc. has been granted a patent in China for its LIBERTY System, a robotic endovascular surgical device. This patent is part of the companys strategy to expand its global intellectual property portfolio, which now includes 9 granted patents and 59 pending applications. The LIBERTY System is designed to assist surgeons in minimally invasive procedures and is expected to launch in the US market in Q3 2025. Microbot Medical is a clinical-stage company focusing on robotic endoluminal surgery devices in Israel and the US. The patent grant is a positive development for the company, enhancing its market position and potential for growth.
Product StagePublic Trading
growth-positive
Microbot Medical® to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual Meeting
Microbot Medical Inc. is set to participate in the inaugural Endovascular Robotics session at the Society of Robotic Surgery annual meeting. The company will present its LIBERTY Endovascular Robotic System, highlighting the growth and innovation in the field of robotic surgery. The session will be moderated by notable figures in the medical field and will provide a platform for Microbot to introduce its technology to the medical community. The company is preparing for the U.S. launch of LIBERTY, pending FDA 510(k) clearance, and is strengthening its sales and marketing infrastructure in anticipation.
Product Stage
growth-positive
Microbot Medical® Added to the Russell Microcap® Index
Microbot Medical Inc. has been added to the Russell Microcap® Index, effective June 30, 2025. This inclusion is seen as a significant milestone, reflecting the companys strong execution and momentum, particularly in relation to its LIBERTY Endovascular Robotic System, which is pending FDA 510(k) clearance. The company is preparing for a Q3 launch and aims to strengthen its operational and commercial infrastructure. Being part of the index enhances Microbot Medicals visibility at a crucial time, as it continues to interact with the FDA and prepare for commercialization. The LIBERTY system is an investigational device and not yet available for sale in the U.S.
Product StagePublic Trading
growth-positive
Companies Like Microbot Medical (NASDAQ:MBOT) Are In A Position To Invest In Growth
Microbot Medical, a company listed on NASDAQ under the ticker MBOT, has seen a significant increase in its share price, rising by 146% over the past year. Despite not generating revenue, the company is in an early stage of development and is focusing on its growth. As of March 2025, Microbot Medical had $30 million in cash and no debt, providing a cash runway of approximately 3.3 years. The companys cash burn rate increased by 19% over the last year, indicating increased investment in its business. While this shortens the cash runway, it suggests a commitment to growth. Investors should consider the companys potential to raise additional funds through new shares or debt.
growth-positive
Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China
Microbot Medical Inc. has been granted a critical patent in China for its LIBERTY Endovascular Robotic System, marking a significant step in its global IP expansion strategy. This patent, covering the robotic manipulation of a surgical tool handle, enhances the companys competitive advantage and supports its long-term global commercialization strategy. The company is preparing for the anticipated U.S. commercial launch of the LIBERTY System in Q3 2025, pending FDA clearance. Microbot Medical aims to expand access to endovascular robotics, improving patient outcomes and procedural capabilities worldwide. The LIBERTY System is currently an investigational device pending FDA 510(k) clearance.
Product StageFDA approved/pending approval
growth-positive
Microbot Medical (MBOT) Upgraded to Buy: What Does It Mean for the Stock?
Microbot Medical Inc. (MBOT) has recently been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates. This upgrade is based on an upward trend in earnings estimates, which is a significant factor influencing stock prices. The Zacks rating system, which tracks changes in earnings estimates, suggests that the companys improving earnings outlook could lead to increased buying pressure and a rise in its stock price. The correlation between earnings estimate revisions and stock price movements is well-documented, and the Zacks Rank system effectively utilizes this relationship to guide investment decisions.
growth-positive
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
Microbot Medical Inc. is preparing for the anticipated U.S. launch of its LIBERTY Endovascular Robotic System in the third quarter of 2025. The company is actively engaged with the FDA, expecting a 510(k) decision in the same timeframe, which aligns with the FDAs original review schedule. To bolster its sales infrastructure and launch execution, Microbot has appointed Michael Lytle as the head of Sales Operations & Analytics. Lytles experience is expected to enhance market intelligence and optimize the sales cycle. The LIBERTY System, currently under FDA review, represents a significant innovation in endovascular robotics, aiming to improve patient care globally.
Management ChangesExpandProduct Stage
growth-positive
Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index
Microbot Medical Inc. announced its inclusion in the preliminary list of additions to the Russell Microcap® Index, which will take effect after the U.S. market closes on June 27, 2025. This inclusion is part of the annual Russell US Indexes reconstitution, capturing the 4,000 largest US stocks by market capitalization. Membership in the index is expected to enhance the companys visibility among investment managers and institutional investors. Microbot Medical is a pre-commercial stage company developing the LIBERTY® Endovascular Robotic System, a single-use, fully disposable system aimed at improving patient care. The company is awaiting FDA clearance for its product, which could impact its commercialization efforts.
growth-positive
Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers
Microbot Medical Inc. is gearing up for the U.S. commercial launch of its LIBERTY® Endovascular Robotic System, pending FDA approval expected in the second quarter of 2025. The company has strengthened its leadership team by appointing Allison Rosefort as Vice President of Marketing and Lisa Dobbins as Director of Human Resources. These strategic hires are part of Microbots efforts to establish a robust commercialization infrastructure. The company is optimistic about the market reception of LIBERTY®, supported by positive data from a pivotal study. The new appointments are expected to drive the companys marketing and human resources strategies, contributing to its growth objectives.
Management ChangesExpand
growth-positive
Is Microbot Medical Inc. (MBOT) the Best Rising Penny Stock to Buy According to Analysts?
The article discusses the performance of small-cap stocks, including Microbot Medical Inc. (NASDAQ:MBOT), in the context of the broader market trends at the start of 2025. Despite challenges such as tariffs, inflation, and recession risks, small-cap stocks are seen as having potential for long-term growth. Francis Gannon from Royce Investment highlights the positive trend of market broadening away from dominant large-cap stocks, which could benefit small caps. He advises investors to remain invested during uncertain times, as small caps are undervalued compared to large caps. The article suggests a growth-positive outlook for small-cap stocks like Microbot Medical Inc.
growth-positive
Microbot posts pivotal surgical robot data; GE Healthcare hires Patient Care Solutions leader
Microbot Medical reported positive results from a pivotal trial of its Liberty Endovascular Robotic System, achieving successful robotic navigation in all 20 procedures without adverse events. The system, designed to reduce radiation exposure for physicians, demonstrated a 92% reduction in radiation exposure and a 100% physician satisfaction rate. The company raised $13 million in February and is anticipating FDA clearance in the second quarter. Additionally, GE Healthcare appointed Jeannette Bankes as the new president and CEO of its patient care solutions business, while Puzzle Medical Devices raised $31 million to advance its heart pump technology.
Product StageInvestmentManagement Changes
growth-positive
Sector Update: Health Care Stocks Gain Late Afternoon
In March, inflation unexpectedly fell, with the core Consumer Price Index (CPI) reaching a four-year low. This development positively impacted health care stocks, including MBOT, which saw a 4.84% increase. The NYSE Health Care Index also rose by 3.3%. This positive market movement suggests a favorable outlook for companies in the health care sector. The article highlights the importance of staying informed about market trends and economic indicators, as they can significantly influence stock performance. The article is part of a premium news service, requiring a subscription for full access.
growth-positive
Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. presented successful results from its ACCESS-PVI pivotal trial for the LIBERTY® Endovascular Robotic System at the Society of Interventional Radiology annual meeting. The study demonstrated a 100% success rate in robotic navigation, a 92% reduction in radiation exposure, and no adverse events. The LIBERTY® system, which is pending FDA 510(k) clearance, is designed to be a single-use, fully disposable endovascular robotic system. The company is preparing for commercial launch, confident in the systems market reception. The trial was conducted at three major U.S. medical centers, and the results were positively received by participating physicians.
Product StagePublic Trading
growth-positive
REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting
Microbot Medical Inc., a pre-commercial stage medical technology company, is awaiting FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System. The company recently presented data from its ACCESS-PVI trial, which evaluates the performance and safety of LIBERTY® in peripheral vascular interventions. The presentation took place at a medical conference, and the company expects the FDAs decision during the current second quarter. Microbot Medical aims to improve patient care with its innovative, single-use, fully disposable robotic system. The article highlights the companys forward-looking statements and the potential risks involved in obtaining regulatory approval and transitioning to a commercially focused entity.
Product StageFDA approved/pending approval
growth-positive
Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has appointed Paul Mullen as Vice President of Sales, marking its first commercial hire as the company prepares for the anticipated FDA clearance of its LIBERTY® Endovascular Robotic System in the second quarter of 2025. Mullen, who has a strong background in sales and market development in the endovascular space, will lead the companys commercial sales efforts in the U.S. His responsibilities include building the sales strategy and infrastructure for a successful product launch. The company is focused on ramping up its commercial readiness in anticipation of FDA approval.
Management Changes
growth-positive
Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting
Microbot Medical Inc. has announced a significant milestone in its collaboration with Corewell Health™ to advance robotic telesurgery for endovascular applications. The collaboration focuses on the feasibility of using the LIBERTY® Endovascular Robotic System for simulated cardiovascular interventional procedures across remote facilities. The research, led by Dr. Ryan Madder, has been accepted for presentation at the Cardiovascular Research Technologies (CRT) annual meeting and will be published in the Journal of the American College of Cardiology (JACC) Interventions. This development highlights the potential of robotic telesurgery to improve access to high-quality healthcare, especially in remote locations.
Partners
growth-positive
Microbot Medical Closes $13 Million Registered Direct Offering
Microbot Medical Inc. announced the closing of a registered direct offering and a concurrent private placement, raising approximately $13 million. The funds will support the development and commercialization of the LIBERTY® Robotic System, expansion of applications from its IP portfolio, and general corporate purposes. The offering was conducted under Nasdaq rules, with H.C. Wainwright & Co. acting as the exclusive placement agent. The common stock was offered via a shelf registration statement filed with the SEC. The company aims to use the proceeds for regulatory activities and working capital.
PIPE
growth-positive
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. announced a registered direct offering and a concurrent private placement to raise approximately $13 million. The company will sell over 6 million shares of common stock at $2.13 per share and issue short-term series I preferred investment options for additional shares. The funds will support the development and commercialization of the LIBERTY® Robotic System, expand applications from its IP portfolio, and cover general corporate expenses. H.C. Wainwright & Co. is the exclusive placement agent. The offering is expected to close around February 11, 2025, pending customary conditions.
PIPE/POInvestment
growth-positive
Why Microbot Medical Inc. (MBOT) Is Skyrocketing So Far In 2025
Microbot Medical Inc, a pre-commercial medical company, is experiencing significant growth in 2025, driven by its focus on robotic endoluminal surgical systems. The company has submitted an FDA 510(k) application for its LIBERTY® system, with clearance expected in Q2 2025, allowing entry into the $2 billion endovascular robotics market. The successful conclusion of the ACCESS-PVI trial in October 2024 further bolsters its prospects. Microbot Medical raised $8.6 million in January 2025, following a $7 million raise earlier in the month. The healthcare sector is rebounding, with AI playing a crucial role in its advancements.
Product StageInvestment
growth-positive
Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting
Microbot Medical Inc. announced the acceptance of a late-breaking abstract for presentation at the Society of Interventional Radiology (SIR) annual meeting. The presentation will cover the results of the ACCESS-PVI trial, which evaluates the performance and safety of the LIBERTY® Endovascular Robotic System. This system is a single-use, fully disposable robotic system designed for peripheral vascular interventions. The acceptance of the abstract highlights the interest in endovascular robotics and the potential benefits of the LIBERTY® system. The company is currently in the clinical trial stage and is awaiting FDA approval for commercial marketing in the United States.
Product Stage
growth-positive
Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®
Microbot Medical Inc. has appointed Ms. Michal Ahuvia as the Director of Operations to enhance operational efficiencies in preparation for the commercial launch of its LIBERTY® Endovascular Robotic System, anticipated in the second quarter of 2025. Ms. Ahuvia, with over 20 years of experience in operations, will focus on ramping up production and improving efficiencies. This strategic move is expected to strengthen the companys manufacturing and operational processes, supporting its transition to a commercially focused entity. The company is currently in the pre-commercial stage and is awaiting FDA clearance for its product.
Management ChangesProduct Stage
growth-positive
Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
Microbot Medical Inc. has announced the election of David J. Wilson to its Board of Directors as part of its transition to a commercially focused company. Wilson brings over 30 years of experience in the endovascular devices market, having held significant leadership roles at Johnson & Johnson and Haemonetics Corporation. His expertise in commercial readiness and product launches is expected to be instrumental as Microbot prepares for the commercial launch of its LIBERTY® Endovascular Robotic System in the second quarter of 2025. This leadership change is seen as a positive step towards achieving revenue growth and strengthening the companys position in the healthcare market.
Management Changes
growth-positive
Microbot Medical Closes $8.6 Million Registered Direct Offering
Microbot Medical Inc. announced the closing of a registered direct offering and a concurrent private placement, raising approximately $8.6 million. The offering involved the sale of 3,788,550 shares of common stock at $2.27 per share and the issuance of short-term series H preferred investment options to purchase up to 7,577,100 shares of common stock. The proceeds will be used for the development and commercialization of the LIBERTY® Robotic System, expansion of applications from the companys IP portfolio, and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent. The offering was conducted under a shelf registration statement filed with the SEC.
PIPE/PO
growth-positive
Microbot Medical prices 3.79M shares at $2.27 in registered direct offering
Microbot Medical has entered into definitive agreements for a registered direct offering and a concurrent private placement, raising approximately $8.6 million. The company will sell 3,788,550 shares of common stock at $2.27 per share and issue short-term series H preferred investment options to purchase up to 7,577,100 shares at $2.10 per share. The proceeds will be used for the development and commercialization of the LIBERTY Robotic System, expansion of applications from its IP portfolio, and general corporate purposes. The closing is expected around January 9, 2025, with H.C. Wainwright & Co. as the exclusive placement agent.
PIPEProduct Stage
growth-positive
Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. announced a registered direct offering and a concurrent private placement to raise approximately $8.6 million. The company will sell 3,788,550 shares of common stock at $2.27 per share and issue short-term series H preferred investment options to purchase up to 7,577,100 shares at $2.10 per share. The proceeds will support the development and commercialization of the LIBERTY® Robotic System and other corporate purposes. H.C. Wainwright & Co. is the exclusive placement agent. The offering is expected to close on January 9, 2025, subject to customary conditions.
PIPE
growth-positive
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility
Microbot Medical Inc. announced the closing of a registered direct offering and a concurrent private placement, raising approximately $11.8 million in total gross proceeds. The funds will be used for the development and commercialization of the LIBERTY® Robotic System, expansion of applications from the companys IP portfolio, and general corporate purposes. The offering included the sale of 4,000,001 shares of common stock and unregistered short-term series G preferred investment options. H.C. Wainwright & Co. acted as the exclusive placement agent. The offering was conducted under a shelf registration statement filed with the SEC.
PIPE/POInvestment
growth-positive
Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. announced a registered direct offering and a concurrent private placement to raise approximately $7 million. The company will issue 4,000,002 shares of common stock at $1.75 per share and unregistered short-term series G preferred investment options to purchase up to 8,000,004 shares. H.C. Wainwright & Co. is the exclusive placement agent. The proceeds will be used for the development and commercialization of the LIBERTY® Robotic System, expansion of applications from the companys IP portfolio, and general corporate purposes. The offering is expected to close around January 7, 2025, pending customary conditions.
PIPE/POInvestment
growth-positive
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
Microbot Medical Inc. is preparing for the commercial launch of its LIBERTY® Endovascular Robotic System in 2025. The company has achieved significant milestones, including the FDA 510(k) submission for commercial approval and completion of the ACCESS-PVI pivotal human clinical trial. They have also established pre-commercial infrastructures and executed strategic initiatives, such as collaborations with Corewell Health and Emory University. These efforts position the company for future growth and success in the medical robotics field.
CustomersPartners
growth-positive
MBOT Stock Gains Following FDA Submission of the LIBERTY System
Microbot Medical Inc. has submitted a 510(k) premarket notification to the FDA for its LIBERTY system, following a successful multi-center trial. The company expects FDA clearance by the second quarter of 2025, with U.S. commercialization to follow. The LIBERTY system, a single-use robotic solution for endovascular procedures, aims to increase procedural efficiency and expand access to robotic-assisted surgeries. Despite a year-to-date share loss of 37.8%, the company sees strong prospects due to positive trial results and physician feedback. Microbot Medical also entered a Phase 2 collaboration with Corewell Health to advance remote telesurgery using the LIBERTY system.
CustomersPartners
growth-positive
Microbot Medical seeks FDA clearance for endovascular robotic system
Microbot Medical has submitted a 510(k) premarket notification to the FDA for its LIBERTY disposable endovascular robotic system, aiming for commercial launch in the US. The system is designed to improve care quality while reducing radiation exposure and physical strain on medical staff. The company anticipates FDA clearance in the second quarter of next year, with commercialization to follow. This marks a pivotal milestone as Microbot Medical transitions to a commercially focused company. The LIBERTY system, positioned to redefine the peripheral endovascular space, is the first commercially available single-use robotic system. The company has partnered with Corewell Health and Emory University to further develop remote telesurgery and autonomous capabilities.
CustomersPartners
growth-positive
Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has submitted a 510(k) premarket notification to the FDA for its LIBERTY® Endovascular Robotic System, marking a significant milestone towards commercialization. The company anticipates receiving FDA clearance in the second quarter of 2025, after which it plans to commence U.S. commercialization. LIBERTY® is the first single-use, fully disposable robotic system for endovascular procedures, designed to improve efficiency, reduce costs, and enhance care quality. The system aims to revolutionize the peripheral endovascular space by eliminating the need for expensive equipment and reducing radiation exposure. Microbot Medical is positioning itself as a leader in medical technology innovation, targeting over 2 million peripheral vascular procedures performed annually in the U.S.
growth-positive
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
Microbot Medical Inc. has announced the submission of its FDA 510(k) application for the commercialization of its LIBERTY Endovascular Robotic System. This innovative system is the first single-use, fully disposable endovascular robotic system, designed to eliminate the need for large capital equipment and improve access to robotics. The LIBERTY system aims to reduce radiation exposure, improve ergonomics, lower procedure costs, and enhance overall care quality. The companys CEO, Harel Gadot, will discuss these developments in a live interview on Benzinga All Access. The submission marks a significant step towards commercialization, potentially leading to growth and adoption in the surgical robotics field.
Customers
growth-positive
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
Microbot Medical, Inc. has completed patient enrollment and follow-up in its ACCESS-PVI human clinical trial, evaluating the LIBERTY Endovascular Robotic Surgical System. The company plans to file a 510(k) submission with the FDA by the end of 2024 and aims to accelerate its market strategy upon clearance. The successful trial completion is a significant milestone, enhancing Microbots position in the healthcare market and supporting future commercialization. The company is preparing for a potential launch in the second quarter of 2025, following anticipated FDA approval. Recent developments include a Phase 2 collaboration with Corewell Health and an agreement with Emory University to explore autonomous robotics in endovascular procedures.
CustomersPartners
growth-positive
Microbot eyes FDA application for surgical robot after completing pivotal trial
Microbot Medical is advancing its go-to-market strategy for its LIBERTY robotic surgical system, anticipating FDA clearance by Q2 2025. The company has completed a pivotal clinical trial ahead of schedule and plans to submit an FDA application by the end of 2024. The LIBERTY system aims to streamline peripheral vascular interventions and reduce the need for large capital equipment. Microbot is also developing remote capabilities for the system, in partnership with Corewell Health, to enable surgeries without a surgeons physical presence. The robotic surgical systems market is expected to grow significantly, driven by demand for less-invasive procedures.
CustomersPartners
growth-positive
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
Microbot Medical Inc. has successfully completed enrollment and follow-up for its ACCESS-PVI human clinical trial, a significant step towards filing a 510(k) submission with the FDA by the end of 2024. The company plans to accelerate its go-to-market strategy, including building a commercial infrastructure and hiring a healthcare executive to lead sales efforts, contingent upon FDA clearance expected in Q2 2025. The LIBERTY® Endovascular Robotic Surgical System aims to revolutionize endovascular procedures by reducing equipment size, cost, and radiation exposure. The trials conclusion and positive physician feedback mark a pivotal moment for Microbot Medical, as it prepares for potential commercialization.
Expand
growth-positive
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
Microbot Medical Inc. announced significant progress in its clinical trial for the LIBERTY® Endovascular Robotic Surgical System. The company has accelerated patient enrollment and completed 80% of the follow-up period, anticipating an earlier trial completion than expected. Microbot Medical remains on track to file its 510(k) submission with the FDA by the end of 2024. Additionally, the company has completed all biocompatibility tests required for its Investigational Device Exemption (IDE) application and received final IDE approval from the FDA. This progress is expected to support the 510(k) submission and subsequent commercialization of the LIBERTY® system.
Customers
growth-positive
Microbot Medical Says it Expects to Finish its ACCESS-PVI Robotic Surgical System Clinical Trial Ahead of Schedule
Microbot Medical announced that it expects to complete its ACCESS-PVI Robotic Surgical System clinical trial ahead of schedule. This development is likely to have a positive impact on the companys growth prospects. The article does not mention any new customers, partners, investments, acquisitions, or layoffs. The announcement was made on September 30, 2024.
growth-positive
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Microbot Medical Inc. has reached the midpoint of its ACCESS-PVI pivotal human clinical trial for the LIBERTY® Endovascular Robotic Surgical System, with 50% of patient enrollment and follow-up completed. The company expects to complete the trial and file a 510(k) submission with the FDA by the end of 2024. The trial aims to evaluate the performance and safety of the LIBERTY® system in Peripheral Vascular Interventions, and successful completion could lead to commercialization. Positive feedback from physicians involved in the trial highlights the systems ease of use and quick setup.
Customers
growth-positive
Microbot Medical advances Liberty Robotic System telesurgery innovation
Microbot Medical Inc has advanced its Liberty Robotic System to the next phase of evaluation, marking a significant milestone in the development of remote telesurgery capabilities. This advancement underscores Microbots commitment to revolutionizing surgical practices through cutting-edge robotic technology. The global market for robotic surgical systems is projected to reach $10 billion by the end of 2024 and $15.8 billion by 2030, driven by the demand for precise, minimally invasive surgical solutions. The Liberty Robotic System aims to address critical challenges in healthcare, including the shortage of skilled surgeons in remote areas and the need for high precision in complex surgeries. This development is expected to contribute to the overall growth of the global surgical robotics market.
CustomersExpand
growth-positive
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
Microbot Medical Inc. has announced a Phase 2 collaboration agreement with Corewell Health to develop the capabilities to perform simulated cardiovascular interventional procedures with LIBERTY, an endovascular robotic surgical system. The partnership follows the successful completion of Phase 1, which demonstrated LIBERTY’s technical capabilities. The project is led by Ryan Madder, M.D., section chief of Interventional Cardiology and director of the Cardiac Cath Lab at Corewell Health. The robotic-assisted endovascular systems market size is expected to surpass $214.7 million by 2033, indicating a promising future for Microbot Medicals partnership with Corewell Health.
PartnersExpand
growth-positive
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has entered into a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures. This follows the successful completion of Phase 1, which demonstrated the technical capabilities of Microbots LIBERTY Endovascular Robotic System. Phase 2 will focus on developing the capabilities to perform simulated cardiovascular interventional procedures with LIBERTY across two sites within the Corewell Health system. The project is led by Ryan Madder, M.D., Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health.
PartnersExpand
growth-positive
Microbot Medical (MBOT) Gets Quality Certification for its System
Microbot Medical Inc. has received ISO 13485:2016 certification for its quality management system, a crucial step towards commercialization and regulatory compliance in the EU and US. The certification will aid in obtaining CE mark approval and transitioning to updated FDA regulations. Microbot Medical is a clinical-stage medical device company developing micro-robotic technologies to improve patient outcomes and access to minimally invasive procedures. The companys LIBERTY Endovascular Robotic Surgical System is designed to revolutionize endovascular procedures by reducing the need for large, costly equipment and minimizing radiation exposure and physician strain.
InvestmentPartners
growth-positive
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
Microbot Medical Inc., a developer of the LIBERTY Endovascular Robotic Surgical System, has received ISO 13485:2016 certification for its quality management system. This certification indicates that the company has robust policies and procedures for the development and manufacture of regulated medical products. The certification is often viewed as the first step in ensuring adherence to European regulatory requirements and is required for CE mark approval for sales in the European Union. The company believes that this certification will help streamline its transition into the revised FDA regulation.
CustomersPartners
growth-positive
Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics
Microbot Medical Inc. has entered into an agreement with Emory University to explore the potential for future collaboration in autonomous robotics in endovascular procedures. The evaluation phase will explore the integration of robotics, procedure planning, and navigation into a single autonomous system. Emory University will explore the feasibility of integrating the LIBERTY Endovascular Robotic Surgical System with an imaging system to create an autonomous robotic system for endovascular procedures. Microbot Medical also entered into a collaboration agreement with Corewell Health to enable telerobotics in remote centers by utilizing the LIBERTY Endovascular Robotic Surgical System.
Partners
growth-positive
Microbot and Emory University to advance endovascular robotic system
Microbot Medical has partnered with Emory University to evaluate the future autonomous capabilities of the Liberty endovascular robotic surgical system. The university will explore the feasibility of integrating the surgical system with an imaging system to create an autonomous robotic system for endovascular procedures. The evaluation will be led by Amir Pourmorteza from Emory University Department of Radiology and Imaging Sciences at the Winship Cancer Institute, and the Department of Biomedical Engineering at Georgia Institute of Technology. Microbot Medical secured the US Food and Drug Administration approval to proceed with its pivotal human clinical trial for its Liberty system in June 2024.
Partners
growth-positive
Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System
Microbot Medical Inc. has announced a partnership with Emory University to explore the potential of autonomous robotics in endovascular procedures. The university will be responsible for exploring the feasibility of integrating the LIBERTY® Endovascular Robotic Surgical System with an imaging system to create an autonomous robotic system for endovascular procedures. The project, named Project Trita, will be led by Amir Pourmorteza, PhD, Assistant Professor in the Department of Radiology and Imaging Sciences at Emory University Winship Cancer Institute, and Department of Biomedical Engineering at Georgia Institute of Technology.
Partners
growth-positive
Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center
Microbot Medical Inc. has received Institutional Review Board (IRB) approval and signed a clinical trial agreement with Memorial Sloan Kettering Cancer Center. The cancer center will conduct the clinical trial as part of the Investigational Device Exemption (“IDE”) for LIBERTY®, Microbots innovative endovascular robotic surgical system. The company expects the trials results will support future marketing submission to the FDA and subsequent commercialization. The trial will be led by Francois Cornelis, MD, PhD. Microbot previously announced that Brigham and Womens Hospital in Boston, and Baptist Hospital of Miami are also enrolled in the trial.
PartnersExpand
growth-positive
Microbot Medical (MBOT) Progresses in Its Human Clinical Trial
Microbot Medical Inc. has announced that the Baptist Hospital of Miami has completed its first clinical procedure using the LIBERTY Endovascular Robotic Surgical System. This is the second site to perform clinical procedures as part of Microbots pivotal human clinical trial, following the first case at Bostons Brigham and Womens Hospital. The progress of the clinical study is encouraging and the company expects the results to support future FDA submission and commercialization of the LIBERTY system. The global robotic-assisted endovascular systems industry is expected to reach $214.7 million by 2033.
CustomersPartners
growth-positive
Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial
Microbot Medical Inc. has announced that Baptist Hospital of Miami has completed its first clinical procedure using the LIBERTY® Endovascular Robotic Surgical System. This is part of the companys pivotal human clinical trial, which is expected to support future FDA submissions for the commercialization of the system. Baptist Hospital is the second site to perform such a procedure, following Brigham & Women’s Hospital. The trial is part of the Investigational Device Exemption for LIBERTY®, and the company expects its results will support future FDA submissions and subsequent commercialization.
CustomersPartners
growth-positive
Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial
Microbot Medical Inc. has announced the successful completion of the first procedure using its LIBERTY® Endovascular Robotic Surgical System at Brigham and Women’s Hospital in Boston, Massachusetts. This marks a significant milestone in the companys pivotal human clinical trial. The results of the trial are expected to support the companys future submission to the FDA and subsequent commercialization of the LIBERTY® system. The company believes that the systems remote operation has the potential to democratize endovascular interventional procedures.
InvestmentExpand
growth-positive
Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial
Microbot Medical Inc. has received Institutional Review Board approval and entered into a Clinical Trial Agreement with Baptist Hospital of Miami for the clinical trial of Microbot’s LIBERTY Endovascular Robotic Surgical System. The partnership is expected to accelerate the development and potential approval of this groundbreaking technology. The company is actively progressing toward gaining approval for the LIBERTY system in the United States and Europe. The global robotic-assisted endovascular systems market was worth $94.0 million in 2023 and is anticipated to reach $214.7 million by 2033.
PartnersExpand
growth-positive
Microbot secures second site for Liberty endovascular robot trial
Microbot Medical has announced the Baptist Hospital of Miami as the second site for the human clinical trial of its Liberty robotic system. The system, which received FDA clearance last month, is a single-use endovascular system designed to increase procedure efficiency. The announcement follows a partnership with Brigham and Women’s Hospital in Boston, Massachusetts, as the first site for the clinical trial. In 2023, Microbot secured $440,000 in funding from the Israel Innovation Authority to further develop its manufacturing process for the Liberty system.
PartnersInvestment
growth-positive
Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY
Microbot Medical Inc. has signed a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System. The company has received approval from the Institutional Review Board to begin the trial at this site. The Baptist Hospital is the second site to participate in the clinical trial for Microbot’s LIBERTY as part of its Investigational Device Exemption (IDE). The company recently announced the Brigham and Womens Hospital as another participating site. The robotic-assisted endovascular systems market size is expected to surpass $214.7 million by 2033.
PartnersExpand
growth-positive
Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial
Microbot Medical Inc. has announced that it has received Institutional Review Board approval and signed a Clinical Trial Agreement with Baptist Hospital of Miami. This makes the hospital the second clinical site to enroll in the trial following the companys recent FDA approval to commence its pivotal human clinical trial. The trial is for Microbots LIBERTY Endovascular Robotic Surgical System. The company had previously announced Brigham and Womens Hospital as another participating site.
PartnersExpand
growth-positive
Transforming surgery: Microbot Medical and Boston hospital collaborate on Liberty Surgical Robot trials
Microbot Medical, a medical technology innovator, has announced a strategic partnership with a prominent Boston hospital to conduct clinical trials of its Liberty Surgical Robot. The collaboration aims to set new standards in surgical precision and patient outcomes by leveraging cutting-edge robotic technology. The global market for robotic surgical systems and their accessories is projected to reach $10 billion by the end of 2024, and surge to $15.8 billion by 2030. The partnership seeks to validate the robot’s capabilities in a clinical setting, paving the way for broader adoption and integration into surgical practices.
PartnersExpand
growth-positive
Microbot partners with Boston Hospital to trial Liberty surgical robot
Microbot Medical has announced that Brigham and Women’s Hospital in Boston will serve as a clinical trial site for its Liberty Endovascular Robotic Surgical System. The Liberty system is a single-use endovascular surgical robotic system designed to improve endovascular procedures. The company has completed a site initiation visit at the centre and has trained staff on the clinical study protocols and the use of the Liberty system. The robotic surgical systems market is projected to grow from $3.3bn in 2023 to $7.2bn in 2033. Microbot is also developing remote capabilities for the Liberty system, allowing the surgical procedure to take place without the presence of the surgeon at the concerned site.
PartnersExpand
growth-positive
Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial
Microbot Medical Inc. has announced its partnership with Brigham and Women’s Hospital (BWH) to conduct a pivotal human clinical trial for its LIBERTY® Endovascular Robotic Surgical System. This follows the FDAs approval to commence the trial. The company has completed the Site Initiation Visit, during which BWH clinical staff was trained on the clinical study protocols and the use of the LIBERTY® Endovascular Robotic Surgical System. The first shipment of LIBERTY investigational systems arrived at BWH in support of the clinical trial.
PartnersCustomers
growth-positive
Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial
Microbot Medical Inc. has announced that Brigham and Women’s Hospital (BWH) will participate as a clinical trial site for its LIBERTY® Endovascular Robotic Surgical System. The company has completed the Site Initiation Visit and delivered a shipment of LIBERTY investigational units to BWH for the clinical trial. Microbot Medical is also in the process of engaging additional leading centers to participate in the clinical trial. The company believes that the LIBERTY® Endovascular Robotic Surgical System’s remote operation has the potential to be the first system to democratize endovascular interventional procedures.
PartnersExpand
growth-positive
Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. has closed a registered direct offering for the purchase and sale of 1,566,669 shares of the company’s common stock at $1.50 per share. In a concurrent private placement, the company has issued unregistered series F preferred investment options. The gross proceeds from the offerings were approximately $2.35 million. The company intends to use the net proceeds for the continued development, commercialization and regulatory activities for the company’s LIBERTY® Robotic System, expansion and development of additional applications derived from the company’s existing IP portfolio, and for working capital and other general corporate purposes.
Investment
growth-positive
Microbot’s LIBERTY robotic system secures FDA approval for pivotal trial
Microbot Medical has received FDA approval to proceed with a pivotal human clinical trial for its LIBERTY robotic endovascular surgical system. The trial is a significant step in the investigational device exemption (IDE) application for the LIBERTY system. The clinical study will be conducted in collaboration with a leading academic medical centre, which has already signed a clinical trial service agreement with Microbot. The company is also working to engage additional medical centres for the trial. In June 2023, Microbot secured funding worth $440,000 from the Israel Innovation Authority to further develop its manufacturing process for the LIBERTY system.
InvestmentPartners
Neutral
Top Midday Gainers
The article is a promotional piece for PremiumMT Newswires, encouraging readers to upgrade their subscription to a Silver or Gold plan in order to access premium news articles. No specific company news, partnerships, or financial details are disclosed.
None
growth-positive
Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. has announced definitive agreements for the purchase and sale of 1,566,669 shares of the company’s common stock at a purchase price of $1.50 per share in a registered direct offering. In a concurrent private placement, the company will issue unregistered series F preferred investment options. The gross proceeds from the offerings are expected to be approximately $2.35 million. The company intends to use the net proceeds for the continued development, commercialization and regulatory activities for the company’s LIBERTY® Robotic System, expansion and development of additional applications derived from the company’s existing IP portfolio, and for working capital and other general corporate purposes.
Investment
growth-positive
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
Microbot Medical Inc. has received approval from the U.S. Food and Drug Administration to proceed with its pivotal human clinical trial for its LIBERTY® Endovascular Robotic Surgical System. The trial will be conducted in the U.S. and the company has signed a clinical trial service agreement with a leading academic medical center. The company is also engaging additional leading centers to participate in the trial. The results of the trial are expected to support a future 510(k) submission.
InvestmentPartners
growth-positive
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
Microbot Medical Inc. has completed the first phase of its collaboration with Corewell Health, which demonstrated the technical capabilities of the LIBERTY Endovascular Robotic Surgical System and outlined potential future applications in a range of endovascular interventions. The collaboration aims to enable telerobotics between remote centers by utilizing the LIBERTY System. The agreement includes the right to mutually evaluate the LIBERTY System for remote procedures. The collaboration is being led by Ryan Madder, M.D., Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health.
Partners
growth-positive
Microbot Medical Shares Status Following Recent Geopolitical Events
Microbot Medical Inc., the developer of the LIBERTY® Endovascular Robotic Surgical System, has announced that despite the ongoing situation in Israel, the companys activities continue without interruption. The company has been working with the FDA on its recent IDE submission and expects to commence its pivotal study in humans as planned. The company has also completed an internal audit in preparation for ISO 13485 certification audits. Microbot Medical has established sufficient inventory of the LIBERTY® Endovascular Robotic Surgical System to support its pivotal study and other ongoing activities. The company is also in discussions with multiple strategic partners for the commercialization of the product.
CustomersPartnersManagement Changes
growth-positive
Microbot Medical (MBOT) Files IDE to Start Human Clinical Study
Microbot Medical Inc. has filed an Investigation Device Exemption (IDE) application with the FDA, which, if cleared, would allow the company to begin its pivotal human clinical study in the United States. The filing is a significant step towards achieving FDA clearance for Microbots LIBERTY Endovascular Robotic Surgical System. The company has also entered into a collaboration with Corewell Health to enable telerobotics between remote centers using the LIBERTY system. The global surgical robots market is expected to reach $11.8 billion by 2029.
InvestmentPartners
Growth-Positive
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
Microbot Medical Inc. has submitted an Investigational Device Exemption (IDE) application to the US Food and Drug Administration (FDA) for its LIBERTY® Endovascular Robotic Surgical System. The application follows the completion of multiple preclinical activities aimed at providing preliminary safety and effectiveness information. If approved, the IDE would allow Microbot to commence its pivotal human clinical trial in the United States. The LIBERTY system aims to improve surgical robotics in endovascular procedures by eliminating the need for large, expensive equipment, reducing radiation exposure and physician strain.
Investment
growth-positive
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
Microbot Medical Inc. has signed a Settlement Agreement and Release with Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd. This resolves all claims asserted against the company by these entities in a lawsuit filed in 2020 relating to a June 2017 securities purchase agreement. The cash payable to the plaintiffs in the settlement, representing over half of the settlement amount, will be covered by Microbot’s insurance carrier. This will not impact the companys cash position or its balance sheet.
Customers
growth-positive
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
Microbot Medical Inc., a pre-clinical medical device company, has announced the addition of a US-based Clinical Research Associate (CRA) to its team. This follows the positive results of its pivotal GLP Pre-Clinical Study for the LIBERTY® Endovascular Robotic Surgical System. The CRA will support the companys anticipated IDE submission to commence its first in human clinical trial. The company believes that the LIBERTY systems remote operation could democratize endovascular interventional procedures by eliminating the need for large, expensive equipment, reducing radiation exposure and physician strain.
Expand
growth-positive
Microbot Medical (MBOT) Announces Positive GLP Study Results
Microbot Medical Inc. has announced the successful completion of its GLP pivotal pre-clinical study, conducted under FDA guidelines. The study used the LIBERTY Endovascular Robotic Surgical System to perform 96 robotic navigations. The positive results are a significant step forward for Microbot Medical, as it transitions from research and development and pre-clinical phase into the clinical, regulatory and pre-commercial phase. The company plans to submit its investigational device exemption (IDE) application to the FDA soon and commence its pivotal human clinical trial. Microbot Medical also recently entered into a collaboration agreement with Corewell Health.
Partners
growth-positive
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Microbot Medical Inc. has entered into an agreement to exercise certain outstanding preferred investment options to purchase up to 1,685,682 shares of common stock at a reduced price. The company will issue new unregistered series E preferred investment options to purchase up to 1,685,682 shares of common stock. The gross proceeds from the exercise of the preferred investment options are expected to be approximately $2.73 million. The company plans to use the net proceeds for the continued development, commercialization and regulatory activities for the Company’s LIBERTY® Robotic System, expansion and development of additional applications derived from the Company’s existing IP portfolio, and for working capital and other general corporate purposes.
Investment
growth-positive
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
Microbot Medical Inc. has successfully completed its GLP pivotal pre-clinical study for the LIBERTY® Endovascular Robotic Surgical System. The study was conducted under FDA-required guidelines and involved 96 robotic navigations performed by three leading interventional radiologists. The positive outcomes of the study have given the company confidence to proceed to the next stage of human clinical studies. Microbot Medical Inc. plans to submit its IDE application to the FDA soon and commence its pivotal human clinical trial.
InvestmentManagement Changes
growth-positive
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic
Microbot Medical Inc. has announced a collaboration with Corewell Health to enable telerobotics between remote centers using the LIBERTY Endovascular Robotic Surgical System. The agreement allows both parties to evaluate the LIBERTY System for remote procedures. The collaboration aims to improve healthcare accessibility, particularly in rural areas, by connecting remote sites. Corewell Health, a not-for-profit health system, provides care and services in 21 hospitals, 300+ outpatient locations, and several post-acute facilities. The LIBERTY System aims to democratize endovascular interventional procedures by eliminating the need for large, expensive equipment, reducing radiation exposure, and physician strain.
Partners
growth-positive
3 Stocks at the Forefront of Medical Robotics
The article discusses the potential of medical robotics stocks, highlighting Globus Medical, Asensus Surgical, and Microbot Medical. It mentions that the global medical robotic systems market reached a valuation of $21.1 billion last year and is projected to generate revenue of $76.4 billion by 2030. Despite the risks associated with investing in these companies, the potential for significant market returns is high. Globus Medical, for instance, posted $384 million in revenue in the third quarter, up 51% year-over-year. Asensus Surgical and Microbot Medical, despite their high-risk profiles, offer potential rewards due to their innovative technologies and the growing market for minimally invasive surgical instruments.
InvestmentCustomers
Growth-Positive
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study
Microbot Medical Inc. has successfully completed its GLP pivotal pre-clinical study for its LIBERTY® Endovascular Robotic Surgical System. The study was conducted under FDA-required guidelines and involved 96 robotic navigations. The positive results of the study will support the companys IDE submission to the FDA to commence its human clinical study. The company is transitioning from R&D and pre-clinical phase into the clinical, regulatory and pre-commercial phase. The LIBERTY® Endovascular Robotic Surgical System aims to improve surgical robotics used in endovascular procedures by eliminating the need for large, expensive capital equipment.
Investment
growth-positive
Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities
Microbot Medical Inc. has announced the appointment of Dr. Juan Diaz-Cartelle as its new Chief Medical Officer (CMO), effective December 1, 2023. The hiring coincides with the companys transition from focusing on research and development in Israel to increasing its U.S.-based activities, including planned clinical trials for the LIBERTY® Endovascular Robotic Surgical System. Dr. Diaz-Cartelle brings extensive experience in the endovascular and interventional space, having previously served as the Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation.
Management ChangesExpand
growth-positive
Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process
Microbot Medical Inc., a pre-clinical medical device company, has announced the successful completion of the Electromagnetic Compatibility (EMC) testing section of the Verification and Validation (V&V) process. This is a key milestone towards regulatory submission and is required to continue the regulatory process with the FDA. The V&V, along with the pre-clinical pivotal study Microbot recently completed, are essential elements to an Investigational Device Exemption (IDE) submission for the FDA to commence clinical trials.
InvestmentExpand
growth-positive
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office
Microbot Medical Inc., the developer of the LIBERTY Robotic Surgical System, has been granted a registered trademark from the US Patent and Trademark Office. The trademark “One & Done” was given to the feature of the LIBERTY Robotic Surgical System which is being developed to integrate guidewires, microcatheters and other instruments required for complete endovascular procedures using the device. The company continues to expand its proprietary assets, including numerous approved and pending patents all over the world.
Investment
growth-positive
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study
Microbot Medical Inc. has announced additional updates regarding positive outcomes of its previously announced pivotal pre-clinical study using the LIBERTY Robotic Surgical System. The study, conducted by three leading interventional radiologists, used the system to reach a total of 48 animal targets. Follow-up examinations showed no visual evidence of vascular injury or any other adverse event. The company expects to receive the comprehensive final report later this quarter and plans on submitting the Investigational Device Exemption (IDE) application to the FDA, in order to commence its pivotal clinical trial in humans.
Investment
growth-positive
Microbot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024
Microbot Medical Inc. has received confirmation to commence the process for its future CE Mark approval, which will allow the company to market its LIBERTY Robotic Surgical System in Europe and other regions accepting the CE Mark. The company will start audits for ISO 13485 certification to ensure compliance with the Quality Management System requirements of the EU Medical Devices Regulation during the first half of 2024. The process will be carried out in parallel with the FDA regulatory process. The company is confident about successfully completing these audits, which will serve as the first step in its commercial approval process for Europe and other regions.
Expand
Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company
Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System
growth-positive
Microbot Medical Engages CRO to Support its Upcoming U.S. Pivotal Clinical Trial
Microbot Medical Inc. has announced a partnership with a Contract Research Organization (CRO) in the U.S. to support its upcoming clinical trial for the LIBERTY® Robotic Surgical System. The CRO will provide comprehensive research management services and guidance throughout the clinical trial process. This partnership is expected to help Microbot navigate the regulatory landscape and achieve necessary compliances with the FDA. The upcoming clinical trial is designed to evaluate the safety and efficacy of the LIBERTY® Robotic Surgical System in endovascular procedures.
PartnersExpand
growth-positive
Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023
Microbot Medical Inc. has announced the growing global recognition of its LIBERTY® Robotic Surgical System, which will be presented in an abstract at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) on September 9, 2023. The presentation follows successful pre-clinical trials with a team of leading European interventional radiologists. The company is finalizing the necessary steps prior to its expected First in Human (FIH) clinical trial and the regulatory process with the FDA in the USA and MDR in Europe.
CustomersPartners
growth-negative
Is Microbot Medical (NASDAQ:MBOT) In A Good Position To Deliver On Growth Plans?
The article discusses Microbot Medicals cash burn and cash runway. It highlights that the company had approximately 11 months of cash runway as of June 2023, which puts it at risk of running out of money. The cash burn reduced by 7.4% over the last year, indicating managements awareness of the depleting cash reserves. However, raising more cash for growth could be challenging for the company, as its cash burn is about 42% of its market capitalization. Overall, the article suggests that Microbot Medicals cash burn is a bit risky and raises concerns about the stock.
Investment
growth-positive
Microbot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical System
Microbot Medical Inc. has signed a manufacturing agreement with B.Y. Medimor Ltd. for the production of its LIBERTY Robotic Surgical System. This agreement is a significant step towards the companys expected first in human clinical trials and subsequent commercialization. B.Y. Medimor will provide manufacturing services for the LIBERTY system, including integration, parts cleaning, clean room assembly, and testing. Microbot Medical aims to improve endovascular procedures by offering a single-use endovascular robotic system that eliminates the need for large, expensive capital equipment. The LIBERTY Robotic Surgical System has the potential to democratize endovascular interventional procedures. The agreement with B.Y. Medimor supports Microbot Medicals transition from a research and development stage to a clinical and commercial stage in the field of endovascular robotics.
Partners
growth-positive
Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board
Microbot Medical Inc., a pre-clinical medical device company specializing in micro-robotic technologies, has announced the expansion of its scientific advisory board (SAB) with the addition of Professor Francois H. Cornelis, a renowned interventional radiologist. Professor Cornelis specializes in minimally invasive image-guided therapies and will bring his expertise to the development of the LIBERTY® Robotic Surgical System. The company expects the contributions of the SAB members to greatly support their forthcoming plans, including clinical trials and collaborations with leading medical centers worldwide.
Management ChangesExpand
growth-positive
Microbot Medical Engaging with a Leading Notified Body to Advance CE Mark for Sales in Europe
Microbot Medical Inc. has announced its plans to obtain European market clearance for its LIBERTY Robotic Surgical System. The company is preparing for an audit for ISO 13485 certification, which will pave the way for obtaining CE Mark for clearance of sales in the European Union. The company is also preparing to obtain EU-MDR certification. The LIBERTY Robotic Surgical System is a single-use endovascular robotic system. The company believes that the system has the potential to revolutionize catheterization by providing a single-use system designed to provide a high degree of stability.
CustomersExpand
Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board
growth-positive
Microbot Medical Successfully Completes an Extensive Pre-Clinical Study Performed in the US
Microbot Medical Inc. announced the successful completion of an extended pre-clinical study for its LIBERTY Robotic Surgical System. The study was conducted by key opinion leaders and executives from the medical industry, with a 100% success rate in reaching vascular targets. Participants provided positive feedback on the systems intuitiveness and remote operation capabilities. The company believes the studys results will support future adoption of the LIBERTY system. Microbot Medical specializes in micro-robotic technologies for medical procedures and aims to improve surgical robotics in endovascular procedures. The LIBERTY system eliminates the need for large capital equipment and reduces radiation exposure and physician strain. The company is focused on advancing in the regulatory process with the FDA and other regions worldwide.
CustomersPartners
growth-positive
Microbot Medical Raises a Total of $7.6 Million in Gross Proceeds from Four Recent Registered Direct Offerings
Microbot Medical Inc. has closed its fourth registered direct offering, generating approximately $2 million in gross proceeds. The company also issued unregistered series D preferred investment options. The net proceeds from the offerings will be used for the development, commercialization, and regulatory activities of the companys LIBERTY Robotic System, as well as the expansion and development of additional applications. The offering was made under a shelf registration statement and a prospectus supplement. The series D preferred investment options were issued in a concurrent private placement. Microbot Medical specializes in micro-robotic technologies for medical devices.
Investment
growth-positive
Microbot Medical Announces $2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. has entered into definitive agreements for a registered direct offering and a concurrent private placement. The company will sell 624,618 shares of common stock at a purchase price of $3.25 per share, and issue unregistered series D preferred investment options to purchase up to 312,309 shares of common stock. The gross proceeds from the offerings are expected to be approximately $2 million. The funds will be used for the development, commercialization, and regulatory activities of the companys LIBERTY Robotic System, as well as the expansion of its IP portfolio and general corporate purposes. The closing of the offerings is expected to occur on or about June 28, 2023.
Investment
growth-positive
Microbot Medical Expand IP protection in Japan
Microbot Medical Inc. has received a Grant of Protection for a Design Patent in Japan, covering the innovative robotic drive of its LIBERTY Robotic Surgical System. This expands the companys global IP portfolio, which already includes 19 patents and 41 pending applications. The Design Patent complements previous protection in Japan, the U.S., Europe, and Israel for the unique design of the LIBERTY Robotic System remote controller. Microbot Medical sees this additional validation and protection as enhancing its intellectual property portfolio and reinforcing its commitment to bringing cutting-edge robotic technologies to healthcare professionals and patients worldwide.
PartnersInvestment
growth-positive
Microbot Medical Announces Multiple Peer Reviewed Abstracts Accepted by The Cardiovascular and Interventional Radiological Society of Europe
Microbot Medical Inc. is encouraged by the positive experiences and satisfaction of Key Opinion Leaders (KOL) using their LIBERTY Robotic Surgical System in pre-clinical animal studies. Two peer-reviewed abstracts have been accepted for presentation at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). The company believes that the accumulation of peer-reviewed data will accelerate the adoption of LIBERTY once it is commercialized. Dr. Eyal Morag, Chief Medical Officer of Microbot Medical, stated that the physicians desire to participate in the studies and submit peer-reviewed abstracts is a testimony to their disruptive solution. The company is also focused on the regulatory process, primarily for the FDA, and aims to improve endovascular procedures with their LIBERTY system.
CustomersPartners
growth-positive
Microbot Medical Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. has closed its registered direct offering and concurrent private placement, raising approximately $1.5 million in gross proceeds. The company sold 701,756 shares of common stock at a purchase price of $2.1375 per share. Additionally, it issued unregistered series C preferred investment options to purchase up to 350,878 shares of common stock. The net proceeds will be used for the development, commercialization, and regulatory activities of the companys LIBERTY Robotic System, as well as for the expansion of its IP portfolio and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offerings.
Investment
growth-positive
Microbot gets IIA grant for endovascular surgical robotic system
Microbot Medical, a pre-clinical medical device company, has received funding worth NIS1.62m ($440,000) from the Israel Innovation Authority (IIA) for its endovascular surgical robotic system LIBERTY. The grant will enable the company to further develop its manufacturing process related to the LIBERTY Robotic Surgical System. This funding is the first time Microbot has secured approval for a grant for the transition from development to manufacturing program. The LIBERTY Robotic Surgical System is designed to improve endovascular procedures by avoiding costly equipment, reducing radiation exposure, and decreasing the workload of physicians. Microbot is also required to pay royalties ranging from 3% to 5% of its future sales of the LIBERTY product as well as interest.
Investment
growth-positive
Microbot Medical Receives a Non-Dilutive Grant from The Israel Innovation Authority Supporting the Development of the Manufacturing Process for its Endovascular Surgical Robotic System
Microbot Medical Inc. has received a grant of NIS 1.62 million (approximately $440,000) from the Israel Innovation Authority to support the development of its flagship robotic surgical system, the LIBERTY. This grant will help establish advanced manufacturing capabilities in-house and ensure the highest quality, efficiency, and reliability of the system. Microbot Medical considers this grant a vote of confidence in the company and its technology. As part of the grant agreement, Microbot will pay royalties on future sales of the LIBERTY product. The grant is linked to the U.S. dollar and bears interest at Libor per annum. Microbot Medical specializes in micro-robotic technologies for medical devices.
Investment
Microbot Medical Announces $1.5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
growth-positive
LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process
Microbot Medical Inc. announces the achievement of an additional milestone in a formative study where medical professionals experienced the companys LIBERTY Robotic Surgical System. The study validated that the systems operation and setup are intuitive, with high subjective grading from participants. The company aims to improve surgical robotics in endovascular procedures by eliminating the need for large, expensive equipment. The study was performed and managed by experts in Human Factors and Usability Engineering tests of medical devices. The company believes that gaining valuable feedback and endorsements from experts will help them progress towards clinical stages and the market.
CustomersPartners
growth-positive
Lahey Hospital & Medical Center Agrees to become One of the U.S. Sites for the LIBERTY® Robotic System’s First Human Trial
Microbot Medical Inc. has announced a major milestone in the development of its LIBERTY Robotic Surgical System, a single-use endovascular robotic system. The company will be partnering with Lahey Hospital & Medical Center for the first-ever human trial of the system. This represents a significant step towards regulatory approval and commercialization of the system. The companys next steps include the submission of the Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) and Institutional Review Board (IRB).
PartnersExpand
growth-positive
Microbot Medical Announces Closing of $2.66 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. has closed a registered direct offering, raising approximately $2,660,900 in gross proceeds. The company plans to use the net proceeds for the development, commercialization, and regulatory activities of its LIBERTY Robotic System, as well as for the expansion and development of additional applications derived from its existing IP portfolio. The offering was made under a shelf registration statement and was facilitated by H.C. Wainwright & Co. The company also amended certain existing warrants to reduce the exercise price. Microbot Medical specializes in micro-robotic technologies for medical devices, with a focus on improving clinical outcomes and increasing accessibility in endovascular procedures.
Investment
growth-positive
3 Undervalued Penny Stocks to Buy for Multi-Bagger Returns
The article discusses three undervalued penny stocks with the potential for high returns. The first stock mentioned is Microbot Medical Inc., which researches and develops micro-robotic technologies for the medical device industry. The companys strong financial position and growth potential make it an attractive investment. The second stock is Eos Energy Enterprises Inc., which operates in the energy storage solutions industry. The company has shown strong revenue growth and operational efficiency, indicating potential for higher earnings. The third stock is EVgo Inc., a prominent player in the U.S. electric vehicle charging space. Despite a drop in stock price, the company is expected to increase sales and expand its charging network. Overall, the article highlights these penny stocks as potentially undervalued investments with the potential for significant returns.
Investment
growth-positive
Microbot Medical Announces $2.66 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. has entered into definitive agreements for the purchase and sale of 1,209,500 shares of the Company’s common stock in a registered direct offering. The offering is expected to generate gross proceeds of $2,660,900, which will be used for the development, commercialization, and regulatory activities of the LIBERTY Robotic System, as well as for working capital and general corporate purposes. The offering is subject to customary closing conditions and is expected to close on or about May 25, 2023. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Investment
growth-positive
Microbot Medical Announces Closing of $1.4 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. has closed its registered direct offering, raising approximately $1,442,252 in gross proceeds. The company plans to use the net proceeds for the development, commercialization, and regulatory activities of its LIBERTY Robotic System, as well as for the expansion of its IP portfolio and general corporate purposes. The offering was made under a previously filed registration statement and was facilitated by H.C. Wainwright & Co. Microbot Medical is a pre-clinical medical device company specializing in micro-robotic technologies for endovascular procedures.
Investment
growth-positive
Microbot Medical Achieved 100% Success Rate for LIBERTY in Extensive Pre-Clinical Animal Study Performed by Leading European Physicians
Microbot Medical Inc. announced the success of an extended joint pre-clinical animal study using their LIBERTY Surgical Robotic System. The study involved six European interventional radiologists who performed 48 catheterizations with a 100% success rate. The radiologists found the system intuitive and easy to use, and the company plans to enter the human clinical phase later this year. The results of the study validate the system and are expected to accelerate early adoption and commercialization. Microbot Medical plans to perform pre-clinical studies in the U.S. and other target markets and aims to democratize endovascular interventional procedures with their remote-operated system.
CustomersPartnersInvestmentExpand
growth-positive
Microbot Medical Announces $1.4 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
Microbot Medical Inc. has entered into definitive agreements for the purchase and sale of shares of the Companys common stock in a registered direct offering. The offering is expected to generate gross proceeds of $1,442,252, which will be used for the development, commercialization, and regulatory activities of the LIBERTY Robotic System, as well as the expansion of the Companys IP portfolio and general corporate purposes. The offering is subject to customary closing conditions and is expected to close on or about May 24, 2023.
Investment
growth-positive
Microbot Medical Stock Shoots Higher: Here's Why
Microbot Medical Inc announced an extended joint preclinical animal study at a European-based research lab. The study showed a 100% success rate in reaching vascular targets using the LIBERTY Robotic System. The company plans to continue preclinical studies and progress towards commercialization. The stock price of Microbot Medical Inc has increased by 146.3%.
Expand
growth-negative
Microbot Medical to Enhance Focus on its Core Business and Prioritize Preparations for Regulatory and First in Human Clinical Cases
Microbot Medical Inc. has announced its Core Business Focus Program and cost restructuring plan to enhance the focus on its core technology, the LIBERTY Robotic Surgical System. The company will eliminate non-core technology expenses and reduce positions not directly supporting the core technology. The goal is to complete the validation and verification process and conduct the first-in-human clinical cases with the LIBERTY system in the second half of 2023. The details of the Core Business Focus Program and cost restructuring plan can be found in the companys Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023. Microbot Medical specializes in micro-robotic technologies for medical devices.
LayoffsExpand
growth-positive
Microbot Medical Initiates Preparations for First-In-Human (FIH) Cases in Brazil for the LIBERTY® Robotic System
Microbot Medical Inc. has engaged with Prof. Francisco Cesar Carnevale to perform the worlds first clinical cases using their LIBERTY Robotic system at the University of Sao Paulo Medical School Hospital in Brazil. This engagement is part of the companys ongoing clinical and regulatory efforts, aiming to obtain regulatory approvals and commercialize their innovative robotic system. The potential clinical cases will begin after the verification & validation process of the LIBERTY Robotic system and obtaining necessary regulatory approvals. Microbot Medical specializes in micro-robotic technologies for improving clinical outcomes and accessibility in endovascular procedures. The LIBERTY Robotic System aims to democratize endovascular interventional procedures by eliminating the need for large, expensive capital equipment.
CustomersPartners
growth-positive
Microbot Medical Announces Final Data From Its Recent Animal Study
Microbot Medical Inc., the developer of the LIBERTY Robotic System, has received a positive histopathology report from the European-based MedTech research laboratory that conducted an animal study for the LIBERTY Robotic System. The study involved 63 navigations to targeted sites using the LIBERTY Robotic System and an equal number of procedures performed manually. The system received positive feedback from physicians and no adverse events were observed. The company believes the results will allow it to focus on the next phases, including a U.S.-based pivotal pre-clinical study.
Investment
Microbot Medical’s LIBERTY® Robotic System Surpasses 100th Catheterization
Gerry O’Sullivan, the Latest Member to Join Microbot Medical’s Scientific Advisory Board, to Leverage Extensive Interventional Radiology Experience to Progress the LIBERTY® Robotic System Through Regulatory, Clinical and Commercialization Phases
Microbot Medical Launches Presence in the United Kingdom as Highly Accomplished Consultant Interventional Radiologist Professor Mark W. Little Joins its Scientific Advisory Board as Efforts to Commercialize the LIBERTY® Robotic System Continue to Accelerate
Microbot Medical Increases Presence in the EU with the Addition of Greece-based Key Opinion Leader Stavros Spiliopoulos, MD, PhD, EBIR-ES, FCIRSE, to its Scientific Advisory Board
Microbot Medical’s Chief Medical Officer Dr. Eyal Morag to Highlight Performance, Safety and Usability Benefits of the LIBERTY® Robotic System During Podium Presentation at Prestigious Robotics Conference
growth-positive
Microbot Medical Secures Patents in Multiple Global Jurisdictions
Microbot Medical has received patents in multiple jurisdictions, expanding and protecting its Intellectual Property (IP) portfolio. The company now has 40 issued/allowed patents and 23 patent applications pending worldwide. The patents cover the companys Self-Cleaning Shunt (SCS) device and guidewire technology for use with endo-luminal interventions. Strengthening the IP portfolio is seen as a critical component of Microbots strategy for facilitating product evolution and maximizing future commercial opportunities. Microbot Medical is a pre-clinical medical device company specializing in micro-robotic technologies for natural and artificial lumens within the human body.
Investment
growth-positive
Microbot Medical to Highlight Progress and Recent Achievements at H.C. Wainwright 6th Annual Israel Conference
Microbot Medical Inc. announced that its CEO, President, and Chairman, Harel Gadot, will be providing an overview of the company and recent progress at the H.C. Wainwright 6th Annual Israel Conference. The conference will also feature virtual one-on-one meetings with Microbot Medicals executives. The company aims to leverage these developments for future commercialization and is excited to share its achievements with investors. A live webcast and archived replay of the presentation will be available on the companys website. Microbot Medical specializes in micro-robotic technologies for medical devices and focuses on natural and artificial lumens within the human body.
InvestmentManagement Changes
growth-positive
Microbot Medical Announces Successful Animal Study Utilizing Its LIBERTY™ Robotic System
Microbot Medical Inc. has successfully concluded its feasibility animal study using the LIBERTY™ Robotic System, the world’s first fully disposable surgical robotic system. The study met all of its end points with no intraoperative adverse events. The system allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, avoiding radiation exposure, physical strain and the risk of cross contamination. The system was operated remotely by two leading physicians in the neuro vascular and peripheral vascular intervention spaces.
InvestmentExpand
growth-positive
Microbot Medical Appoints the Co-Founder of Corindus Vascular Robotics to its Board of Directors
Microbot Medical Inc. has appointed Tal Wenderow, an experienced medical device and robotics executive, to the Companys Board of Directors. Wenderow co-founded Corindus Vascular Robotics and contributed to its success before its acquisition by Siemens Healthineers AG. Microbot Medical expects Wenderows expertise to contribute greatly to the future success of the company, particularly in the development and commercialization of the LIBERTY Robotic system. Wenderow has over 19 years of industry experience and is currently the President and CEO of Vocalis Health. Microbot Medical specializes in micro-robotic technologies for medical applications.
Management Changes
growth-positive
Microbot Medical Appoints Aileen Stockburger to the Board of Directors
Microbot Medical announced the appointment of Aileen Stockburger to the Companys Board of Directors. Ms. Stockburger has extensive expertise in strategizing, managing, and closing mergers and acquisitions, licensing agreements, and divestitures. Her experience in merger and acquisition transactions as well as strategic collaborations will enhance the companys ability to achieve its growth objectives. Microbot Medical specializes in micro-robotic technologies for medical devices and aims to improve clinical outcomes and accessibility. The companys progress in developing advanced robotic systems for healthcare has attracted Ms. Stockburger to join the Board.
Management Changes
growth-positive
Microbot Medical Appoints Eyal Morag M.D. as Chief Medical Officer
Microbot Medical Inc. has appointed Eyal Morag, M.D. as Chief Medical Officer. Dr. Morag will lead the development and execution of the clinical strategy for the companys technology platforms. He will focus on the development of the Self-Cleaning Shunt (SCS) and LIBERTY products, as well as future pipeline projects. Dr. Morag is a leading radiologist and has been a member of the companys Scientific Advisory Board since 2017. His appointment is seen as a positive growth move for the company, as it transitions from product development to clinical validation and regulatory phases.
Management Changes
growth-positive
Microbot Medical Receives Intention to Grant from European Patent Office for a Patent Application Covering its Self-Cleaning Shunt
Microbot Medical Inc. has received an official communication from the European Patent Office regarding the granting of a patent for its Self-Cleaning Shunt. The company now has a total of 36 patents issued/allowed and 16 patent applications pending worldwide. The patent covers an inlet head for use on shunts, which are implanted in Hydrocephalus patients for draining excess cerebrospinal fluid. Microbot Medical specializes in micro-robotic technologies for medical devices and aims to develop a multi-generation product portfolio. The companys latest introduction is the LIBERTY Robotic System, the worlds first fully disposable robotic system for use in neurovascular, cardiovascular, and peripheral vascular procedures.
PartnersExpand
growth-positive
Microbot Medical Inc. Announces Closing of $10.0 Million Registered Direct Offering of Common Stock
Microbot Medical Inc. has closed its registered direct offering of common stock, raising approximately $10.0 million in gross proceeds. The company plans to use the net proceeds for the development and regulatory activities of its SCS device for the treatment of hydrocephalus and NPH, the expansion of its LIBERTY robotic system, the development of additional applications from its existing IP portfolio, and for general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. Microbot Medical is a pre-clinical medical device company specializing in micro-robotic technologies for natural and artificial lumens within the human body.
Investment
growth-positive
Microbot Medical to Unveil World's First Fully Disposable Robotic System for Endovascular Procedures
Microbot Medical has announced the revealing of LIBERTY, the world’s first fully disposable robotic system for use in neurovascular, cardiovascular, and peripheral vascular procedures. The LIBERTY robotic system features a unique compact design with remote operation capabilities and the potential to eliminate the use of multiple consumables. The company plans to publicly display and demonstrate LIBERTY on January 13, 2020, in San Francisco. The system aims to revolutionize surgical robotics by reducing radiation exposure, physical strain, and the need for capital equipment. It also aims to streamline the use of disposables during complex procedures. Dr. Eyal Morag will be performing live demonstrations of LIBERTY, highlighting its capabilities. The system is expected to be welcomed by the interventional community and has the potential to democratize endovascular interventional procedures.
CustomersPartners
growth-positive
Microbot Medical's Self-Cleaning Shunt (SCS™) Clearly Demonstrated the Ability to Prevent Shunt Occlusion in a Follow-up In-vitro Laboratory Study
Microbot Medical Inc.s Self-Cleaning Shunt (SCS) has been validated in a follow-up in-vitro lab study, demonstrating its capability to prevent shunt occlusion. The study showed significant cell growth and accumulation in a non-operating SCS, as well as a standard of care surgical shunt. However, the operating SCS effectively prevented cell blockage. The company remains on track to release the results of pre-clinical studies in the fourth quarter of 2019 and the first quarter of 2020. Microbot Medical Inc. specializes in micro-robotic medical technologies and is developing the SCS for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH).
Customers
growth-positive
Microbot Medical Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market
Microbot Medical Inc. has entered into definitive agreements with institutional investors for the purchase of 250,000 shares of its common stock in a registered direct offering priced at $10.00 per share. The company has also agreed to issue unregistered warrants to purchase up to 250,000 shares of common stock. The closing of the offering is expected to occur on or about January 25, 2019. The gross proceeds to Microbot are expected to be approximately $2.5 million. The company intends to use the net proceeds for the development of its SCS device, expanding its IP portfolio, and for general corporate purposes. The shares of common stock are being offered under a shelf registration statement. A final prospectus supplement and accompanying base prospectus will be filed with the SEC.
Investment
growth-positive
Microbot Medical Showcases a Working Prototype of its Self-Cleaning Shunt
Microbot Medical demonstrated an activated Self-Cleaning Shunt (SCSTM) during investor and analyst meetings. The SCSTM was activated from a working prototype of a customized headset. The company received positive feedback and interest from the professional community. The SCSTM is designed to prevent obstruction in the cerebrospinal fluid catheters implanted in the brain. Microbot Medical specializes in micro-robotic medical technologies and is developing its first product candidate, the SCSTM. The company became a NASDAQ listed company in 2016.
Investment
growth-positive
Microbot Medical Inc. Announces $5.9 Million Registered Direct Offering Priced At-the-Market
Microbot Medical Inc. has entered into definitive agreements with several institutional investors for the purchase of 590,000 shares of its common stock in a registered direct offering. The offering is expected to result in approximately $5.9 million in gross proceeds for Microbot. The company plans to use the net proceeds for the development of its SCS device, expanding its IP portfolio, and for general corporate purposes. The offering is expected to close on or about January 17, 2019.
Investment
growth-positive
Microbot Medical Increases its Global IP Portfolio with Notice of Allowance from the European Patent Office
Microbot Medical Inc. has received a notification from the European Patent Office that it will grant a patent for its ViRob technology platform. This strengthens the companys global intellectual property estate and reinforces its pillars for success. The ViRob technology is a crawling micro-robot that can navigate and crawl within the human body. Microbot Medical specializes in micro-robotic medical technologies and is developing its first product candidate, the Self Cleaning Shunt, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The company has a total of 30 issued/allowed patents and 18 patent applications pending worldwide.
Investment
growth-positive
Recent Study Validates the Operational Effectiveness of Microbot Medical's Self-Cleaning Shunt (SCS™)
Microbot Medical has announced the successful validation of its Self-Cleaning Shunt (SCSTM) in an independent in-vitro laboratory study. The study demonstrated the devices ability to prevent shunt occlusion, leading to potential advancements in the treatment of conditions such as Hydrocephalus and Normal Pressure Hydrocephalus (NPH). The company plans to explore additional medical applications for the device, including in the Traumatic Brain Injury (TBI) space. Microbot Medical previously announced positive data from pre-clinical studies and is currently conducting a follow-up study to validate the safety and efficacy of the SCSTM. The company aims to conclude the study and announce the data in the second half of 2019.
Customers
growth-positive
Microbot Medical Announces FDA Pre-Submission Milestones for 2019
Microbot Medical Inc. announced anticipated operational and product milestones for 2019, including pre-clinical study and FDA pre-submission milestones. The company achieved key objectives in 2018, such as completing pre-clinical studies, expanding its portfolio of technologies, and strengthening its management team. These achievements position Microbot to achieve milestones in 2019, including announcing the results of an independent in-vitro study, completing a pivotal pre-clinical study, and finalizing the FDA regulatory pre-submission request. The company also plans to strengthen its balance sheet, explore related market opportunities, expand its global IP portfolio, and build out its senior leadership. Microbot specializes in micro-robotic medical technologies and is developing the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH).
InvestmentManagement Changes
growth-positive
Microbot Medical Announces Commencement of Pivotal Study for its Self-Cleaning Shunt
Microbot Medical Inc. has announced the commencement of a follow-up pivotal study to evaluate the safety and efficacy of its Self-Cleaning Shunt (SCS) device. The SCS is designed to prevent obstruction in the cerebrospinal fluid catheters implanted in the brain of patients with hydrocephalus or Normal Pressure Hydrocephalus (NPH). The follow-up study will be conducted by hydrocephalus experts at Washington University and Wayne State University. The study aims to validate the safety and efficacy of the SCS through in-vitro and in-vivo models. Microbot Medical plans to use the findings for regulatory submissions in the US, Europe, and other jurisdictions. The company aims to conclude the follow-up studies and publish the data in mid-2019.
Customers
growth-positive
Microbot Medical Strengthens Global IP with Issued Patent in India Covering the Company's ViRob™ Technology Platform
Microbot Medical has been granted a patent in India for its ViRob technology platform. The company sees this patent, along with recent notices of patent allowance in China and the EU, as a sign of its commitment to expanding and protecting its assets in both developed and developing markets. Microbots CEO believes that their Self-Cleaning Shunt (SCS) product, which uses the ViRob technology, has the potential to become the global standard of care for hydrocephalus. The company is focused on developing a Multi Generation Pipeline Portfolio (MGPP) utilizing its technological platforms. Microbot Medical specializes in transformational micro-robotic medical technologies for use within the human body.
Investment
growth-positive
Microbot Medical Announces Successful Completion of Pre-Clinical Study Performed at Washington University in St. Louis
Microbot Medical Inc. announced the results of a pre-clinical study assessing the safety profile of their Self-Cleaning Shunt (SCS™) product. The study showed that the cellular response to the SCS™ is confined to the normal foreign body reaction and is no different than the response to a standard implanted CSF drainage catheter. The company plans to move forward with the development of the SCS™ and commence larger scale studies to support regulatory submissions. The results of the study, combined with other milestones achieved by the company, provide a high degree of confidence in their development plans. Microbot Medical specializes in the design and development of micro-robotic medical technologies.
Customers
growth-positive
Microbot Medical Closes Acquisition of Novel Technology from CardioSert Ltd.
Microbot Medical Inc. has announced the closing of its acquisition of a novel patent-protected technology from CardioSert Ltd. The acquisition includes CardioSerts innovative technology, R&D information, technical know-how, and intellectual property. Microbot believes that this acquisition, combined with its existing capabilities and recent pre-clinical results, will allow the company to deliver highly differentiated robotic products to address unmet medical needs. The acquisition was made in exchange for 100,000 restricted shares of Microbots common stock and a cash payment of $250,000 at closing, with potential additional milestone payments and earn-outs. The CardioSert technology was originally developed to support interventional cardiologists in crossing complex lesions, but Microbot sees potential applications in other areas such as peripheral intervention, neurosurgery, and urology.
Acquisition
News and Insights
growth-positive
Microbot Medical Exercises Option to Acquire Novel Technology from CardioSert Ltd.
Microbot Medical Inc., a medical device company, has announced the acquisition of a novel patent-protected technology from CardioSert Ltd. The acquisition strengthens Microbots IP portfolio and creates additional barriers to entry while expanding its addressable markets. The technology has the potential to be used in various medical spaces and applications. The closing of the acquisition is expected in late April. Microbot will own CardioSerts technology in exchange for 100,000 restricted shares of Microbots common stock and a cash payment of $250,000. The technology was originally developed to support interventional cardiologists in crossing complex lesions during procedures, but Microbot believes it can be used in other areas such as peripheral intervention, neurosurgery, and urology. Microbot is confident in its ability to deliver on its promises and increase shareholder value.
Acquisition
growth-positive
Microbot Medical Announces Appointment of Chief Technology Officer
Microbot Medical Inc. has appointed Mr. Simon Sharon as Chief Technology Officer. The company aims to complete ongoing studies related to its first product, the Self-Cleaning Shunt (SCS), and close the previously announced acquisition of CardioSert. Microbot plans to explore additional strategic opportunities and strengthen its development team to meet milestones and expand its portfolio. Mr. Sharon, a seasoned medical device executive, brings over 30 years of industry experience to the role. He previously served as the Chairman of Microbots Scientific Advisory Board and held various positions in medical device companies. Microbot Medical specializes in micro-robotic medical technologies for the human bodys natural and artificial lumens.
Management Changes
growth-positive
Microbot Medical Inc. Announces European Patent Office's Intent to Grant Patent for Device for the Prevention of Shunt Stenosis
Microbot Medical Inc. has announced that the European Patent Office will grant a patent for their device for the prevention of stenosis in blood vessels. The patent will cover the use of the device on blood vessels adjacent to a hemodialysis shunt. The company sees this as a success in expanding their intellectual property platform, especially in the EU market. Microbot Medical specializes in the design and development of micro-robotic medical technologies and is currently developing its first product candidate, the Self Cleaning Shunt, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The company aims to secure and pursue additional patents in the coming months.
Partners
growth-positive
Microbot completes merger with Stem Cell
Israeli company Microbot has completed its merger with Nasdaq-listed US company Stem Cell. Microbot develops miniature robots for cleaning drainage pipes in the body. The merger has resulted in Microbots current shareholders owning 95% of the company. Stem Cells market cap rose to $450 million following the merger. MEDX Ventures Group and private investors have invested $6 million in Microbot to date. The company expects to obtain FDA approval for marketing its product in the US in the near future.
AcquisitionInvestment
growth-positive
Microbot Medical Closes Merger Transaction;Initiates Trading on NASDAQ as 'MBOT'
Microbot Medical has closed its merger transaction with StemCells, Inc. and has become a wholly-owned subsidiary of StemCells. The company will be renamed Microbot Medical Inc. and will begin trading on NASDAQ. Microbot Medical specializes in the design and development of micro-robotic medical technologies and is focused on improving surgical procedures and outcomes. The completion of the merger allows Microbot Medical to capitalize on its core capabilities and fund the development of its next generation of micro-robotic medical products. The company anticipates FDA submission for its lead product candidates in the near future and expects its robust pipeline to drive revenue prospects in the short, mid, and long term.
AcquisitionPublic Trading
growth-positive
7 Israeli robots that are transforming surgery
The article discusses the advancements and innovations in robotic surgery, particularly in Israel. It highlights the contributions of Israeli companies in the field of surgical robotics and their impact on the medical industry. The article mentions several Israeli companies involved in developing robotic surgical systems, such as Mazor Robotics, MedRobotics, MST, Human Extensions, Microbot Medical, XACT Robotics, and Memic Innovative Surgery. These companies have developed various robotic systems and tools for different surgical procedures, including spinal surgery, head and neck surgery, laparoscopic surgery, and more. The article emphasizes the growth and potential of robotic surgery, with major companies like Google, IBM, and Apple investing in this technology. The date of the event described in the article is not mentioned.
PartnersInvestment
Microbot Medical Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 37 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 7 classification IDs that could be used for matching.
Microbot Medical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 514519412 |
| Crunchbase | microbot-medical |
| Phone | +97248200710 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-10-10T00:00:00.000Z |
| Created | 2015-09-29T00:00:00.000Z |
| Status detail | Public on NASDAQ on Nov, 2016; |